According to this criterion, a total of 13 B-ALL cases with aberrant activation of GATA2 were identified from 7 subtypes (Figure 1B), accounting for 2.07% of B-ALL cases. This evidence concerns the gene GATA2 and acute lymphoblastic leukemia.